CURATIVE HEALTH SERVICES INC

Form 8-K/A May 03, 2002

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K/A

AMENDMENT NO. 1 TO CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 28, 2002

CURATIVE HEALTH SERVICES, INC. (Exact name of registrant as specified in its charter)

Minnesota 000-19370 41-1503914 (State or other jurisdiction of incorporation or organization) File Number) Identification No.)

150 Motor Parkway Hauppauge, New York 11788 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (631) 232-7000

5051 Highway 7, Ste. 100, St. Louis Park, MN 55416 (Former name or former address, if changed since last report.)

This amendment is being filed to revise Item 7 in the Registrant's current report on Form 8-K filed March 11, 2002, to include the historical and pro forma financial information required by paragraphs (a) and (b) of Item 7 which were omitted from the report as initially filed in accordance with paragraph (a) (4) of Item 7.

- Item 7. Financial Statements and Exhibits
 - (a) Financial Statements of Business Acquired
 - (1) The report of independent auditors, audited balance sheets, related audited statements of income and retained earnings and cash flows of Apex Therapeutic Care, Inc. as of and for the years ended September 30, 2001 and 2000.
 - (2) The report of independent auditors, audited balance sheets, related audited statements of income and retained earnings and cash flows of Apex Therapeutic Care, Inc. as of and for the years ended September 30, 2000 and 1999.
 - (3) The unaudited condensed statements of operations, unaudited condensed balance sheets and unaudited condensed statements of cash flows as of and for the quarters ended December 31, 2001 and 2000.

(b) Pro Forma Financial Information

The unaudited pro forma consolidated balance sheet and statement of operations of Curative Health Services, Inc. and Subsidiaries as of and for the year ended December 31, 2001.

(c) Exhibits

23.1 Consent of Martini, Iosue & Akpovi

APEX THERAPEUTIC CARE, INC.
FINANCIAL STATEMENTS
AS OF AND FOR THE YEARS ENDED
SEPTEMBER 30, 2001 AND 2000

TABLE OF CONTENTS

Independent Auditors' Report

Balance Sheets

Statements of Income and Retained Earnings

Statements of Cash Flows

Notes to Financial Statements

3

INDEPENDENT AUDITORS' REPORT

To the Board of Directors Apex Therapeutic Care, Inc. Westlake Village, California

We have audited the accompanying balance sheets of Apex Therapeutic Care, Inc. as of September 30, 2001 and 2000 and the related statements of income and retained earnings and cash flows for the years then ended. These financial statements are the responsibility of Apex Therapeutic Care, Inc.'s management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes

assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Apex Therapeutic Care, Inc. as of September 30, 2001 and 2000 and the results of its operations and its cash flows for the years then ended in conformity with generally accepted accounting principles.

/s/ Martini, Iosue & Akpovi

Encino, California November 30, 2001

4

APEX THERAPEUTIC CARE, INC.
BALANCE SHEETS
SEPTEMBER 30, 2001 AND 2000

	2001	2000
ASSETS		
CURRENT ASSETS Cash Accounts receivable (net of allowance for doubtful accounts of \$567,490 and \$543,828) Inventory Other current assets	\$ 757,244 11,794,313 3,804,779 69,677	\$ 54,080 11,073,189 1,884,478 82,817
TOTAL CURRENT ASSETS	16,426,013	13,094,564
PROPERTY AND EQUIPMENT, NET	230,836	237,716
OTHER ASSETS Deposits Deferred tax assets, net Due from related party Other assets, net	22,933 581,342 39,638 37,888	22,267 377,864 -0- 77,476
TOTAL OTHER ASSETS	681,801	477,607
TOTAL ASSETS	\$17,338,650	\$ 13,809,887
LIABILITIES AND STOCKHOLDE	ERS' EQUITY	
CURRENT LIABILITIES Accounts payable and accrued expenses Income taxes payable Current portion of notes payable	\$ 6,122,670 108,883 8,630	\$ 4,542,717 184,584 14,763

Due to related party Note payable - related party Dividends payable	-0- -0- 500,000	32,454 925,922 -0-
TOTAL CURRENT LIABILITIES	6,740,183	5,700,440
LONG-TERM LIABILITIES Deferred compensation Line of credit Notes payable	151,311 -0- 52,282	80,937 1,499,456 89,268
TOTAL LONG-TERM LIABILITIES	203,593	1,669,661
TOTAL LIABILITIES	6,943,776	7,370,101
COMMITMENTS AND CONTINGENCIES		
STOCKHOLDERS' EQUITY Common stock, stated value, authorized 1,000,0	00	
shares issued and outstanding 100,000 shares Common stock - restricted, issued and outstand	210,000 ling	210,000
20,000 shares	395 , 626	56,518
Retained earnings	9,789,248	6,173,268
TOTAL STOCKHOLDERS' EQUITY	10,394,874	6,439,786
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$17,338,650 ======	\$13,809,887 ======

The accompanying notes are an integral part of these financial statements.

5

APEX THERAPEUTIC CARE, INC. STATEMENTS OF INCOME AND RETAINED EARNINGS FOR THE YEARS ENDED SEPTEMBER 30, 2001 AND 2000

	2001	2000
NET SALES COST OF SALES	\$54,536,664 37,821,316	
GROSS PROFIT	16,715,348	12,887,484
OPERATING EXPENSES	9,558,269	8,552,586
INCOME FROM OPERATIONS	7,157,079	4,334,898
OTHER INCOME (EXPENSES) Miscellaneous income Interest income Loss on disposal of assets Miscellaneous expense Interest expense	8,509 3,030 (3,780) -0- (274,650)	-0- -0- (19,263) (23,987) (583,346)
NET OTHER EXPENSES	(266,891)	(626 , 596)

	========	========
End of year	\$ 9,789,248	\$ 6,173,268
Dividends	(500,000)	-0-
Beginning of year	6,173,268	3,910,482
NET INCOME RETAINED EARNINGS	4,115,980	2,262,786
PROVISION FOR INCOME TAXES	2,774,208	1,445,516
INCOME BEFORE PROVISION FOR INCOME TAXES	6,890,188	3,708,302

The accompanying notes are an integral part of these financial statements.

6

APEX THERAPEUTIC CARE, INC. STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2001 AND 2000

	2001	2000
CASH FLOWS FROM OPERATING ACTIVITIES		
Net income	\$4,115,980	\$2,262,786
Adjustments to reconcile net income to net cash provided by operating activities:		
Provision for bad debts	23,662	395,000
Amortization and depreciation	119 , 587	108,160
Loss on disposal of assets	3 , 780	
Deferred income tax benefit	(203, 478)	(321,542)
Deferred compensation		184,968
Stock-based compensation	339,108	
(Increase) decrease in assets:		
Accounts receivable	(744,786)	868,672
Inventory	(1,920,301)	(584,722)
Deposits	(666)	1,075
Due from related party	(39,638)	
Other assets, net	13,789	(62,336)
Increase (decrease) in liabilities:		
Accounts payable and accrued expenses	1,579,953	(221,145)
Income taxes payable		(1,612,207)
Due to related party	(32,454)	-0-
NET CASH PROVIDED BY OPERATING ACTIVITIES	3,249,209	1,094,490
CACH HOED DV INVECTING ACTIVITIES		
CASH USED BY INVESTING ACTIVITIES Purchase of property and equipment	(77 540)	/1C2 00E)
rurchase of property and equipment	(77,540)	(163,895)
CASH FLOWS FROM FINANCING ACTIVITIES Principal payments on note payable to related		
party	(925,922)	(701,323)
Net increase (decrease) in line of credit	(1,499,456)	(415,028)
Principal payments on notes payable	(43,119)	
Proceeds from sale of common stock	-0-	200,000

NET CASH USED BY FINANCING ACTIVITIES	(2	2,468,497)	 (916,351)
NET INCREASE IN CASH		703,164	14,244
CASH, BEGINNING OF YEAR		54,080	39,836
CASH, END OF YEAR	\$	757 , 244	\$ 54 , 080

The accompanying notes are an integral part of these financial statements. 7

APEX THERAPEUTIC CARE, INC. NOTES TO FINANCIAL STATEMENTS SEPTEMBER 30, 2001 AND 2000

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Apex Therapeutic Care, Inc. (the "Company") is a wholesale distributor of pharmaceutical products consisting primarily of antihemophilic factors and other plasma derived therapeutic agents. The Company's sales are made to pharmacies located in various states throughout the continental United States.

Accounts Receivable

The allowance for doubtful accounts is based on management's evaluation of outstanding accounts receivable at the end of the year given their prior experience with third party insurance company receivables. Bad debt expense for the years ended September 30, 2001 and 2000 was \$345,455 and \$817,564, respectively.

Inventory

Inventory is stated at the lower of average cost (which approximates first in, first out) or market. Inventory consists of finished goods.

Property and Equipment

Property and equipment are recorded at lower of cost or net realizable value. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from five to seven years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Maintenance and repairs are charged to expense as incurred.

Other Assets, Net

Other assets consist principally of deferred financing fees, organizational costs and security deposits. The deferred financing fees are amortized straight-line over the term of the financing facility. The organizational costs are amortized straight-line over ten years. Accumulated amortization

for the deferred financing fees was \$80,252 and \$41,730 and accumulated amortization for organizational costs was \$1,457 and \$1,041 at September 30, 2001 and 2000, respectively.

8

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amount of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Use of Estimates

Management of the Company has made a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities to prepare these financial statements in conformity with generally accepted accounting principles. Actual results could differ from those estimates.

Concentration of Credit Risk

As of September 30, 2001, the Company had an account with a bank which exceeded the \$100,000 federally insured limit.

Reclassifications

Certain income statement accounts reported on the financial statements for September 30, 2000 have been reclassified to conform to the financial statement reclassifications for September 30, 2001.

9

NOTE 2 - PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at September 30:

	2001	2000
Computer hardware and software	\$174,139	\$114,539
Office furniture and equipment	127,801	124,484
Leasehold improvements	54 , 306	52,606
Warehouse equipment	23,779	20,479

	======	
Property and equipment, net	\$230,836	\$237,716
Less: Accumulated depreciation	(155,082)	(76 , 177)
	385,918	313,893
Convention equipment	5,893	1,785

NOTE 3 - LINE OF CREDIT

In August 1999, the Company entered into a credit facility with a lender that permits the Company to borrow up to 80% of its eligible receivables. The credit facility has a maximum borrowing limit of \$6,500,000 and expires August 15, 2002. Interest on advances under the terms of this credit facility accrues at a per annum rate of one percent (1%) in excess of the rate of interest announced publicly by Citibank, N.A., from time to time as its "prime rate" (6.0% and 9.5% at September 30, 2001 and 2000, respectively) and is payable monthly. The Company must pay a quarterly fee equal to one-half of one percent (0.5%) on the unused portion of the facility. Amounts owed to the bank under this credit facility are secured by all assets of the Company. The balance outstanding at September 30, 2001 and 2000, was \$0 and \$1,499,456, respectively.

NOTE 4 - STOCKHOLDERS' EQUITY

In November 1999, the Company sold 2,000 shares of common stock to an officer of the Company for \$200,000. Subsequently, the Board of Directors amended and restated the Company's articles of incorporation to effect a ten-for-one split of the Company's outstanding common stock. The split of the Company's stock was effected in the form of a stock dividend. Pursuant to the amendment, the Company is authorized to issue 1,000,000 shares of its common stock of which 100,000 shares were issued and outstanding as of September 30, 2001 and 2000.

10

NOTE 5 - STOCK APPRECIATION RIGHTS

In October 1999, the Company adopted a non-qualified Stock Appreciation Rights Plan (SAR Plan), whereby selected key employees are granted performance unit rights (SAR Units) which are rights to receive an amount based on the appreciated value of the Company's common stock over an established base price. SAR Units begin vesting on the date of grant and vest at 20% per year for five years. The maximum number of SAR Units that may be granted under the plan is 10,000. The maximum term of the plan is ten years. On October 1, 1999, the Company issued 6,750 SAR Units at a weighted average-base price of \$0.125 per unit. The date of grant for these units was deemed by the Company's Board of Directors to be April 1, 1998.

During the year ended September 30, 2001, 250 SAR Units were exercised. Upon the exercise of the SAR Units, the appreciated value was determined and paid to the employee.

During the year ended September 30, 2000, 2,250 SAR Units were exercised. Upon the exercise of the SAR Units, the appreciated value was determined and the amounts were converted into Notes Payable with a term of 84 months. The notes are subordinate to any amounts due under the Company's Line of Credit Agreement and bear interest at 9% per annum.

The principal portion of these notes matures as follows during the years ending September 30:

2002	\$ 8,630
2003	9,439
2004	10,325
2005	11,293
2006	12,353
Thereafter	8,872
	\$60,912

During the year ended September 2000, an employee forfeited rights to $3,500\ \mathrm{SAR}$ Units.

Outstanding SAR Units at September 30, 2001 and 2000 were 750 and 1,000, respectively. Deferred compensation expense related to the outstanding units during the years ended September 30, 2001 and 2000 were \$70,374 and \$184,968, respectively.

11

NOTE 6 - PROVISION FOR INCOME TAXES

The provision (benefit) for income taxes for the years ended September 30, 2001 and 2000 consists of the following:

	2001	2000
Current	\$2,977,686	\$1,767,058
Deferred	(203, 478)	(321,542)
	\$2,774,208	\$1,445,516
	=======	=======

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities at September 30, 2001 and 2000 are presented below:

Deferred tax assets:

	2001	2000	
Accounts receivable principally due			
to allowance for doubtful accounts	\$243,113	\$232,976	
Inventory	10,359	6 , 075	
Accrued stockholder bonus	-0-	32,130	
Accrued commissions	86,712	31,172	
Accrued vacation	23,235	185	
Deferred compensation	64,822	64,416	
Stock-based compensation	169,486	24,212	
Total deferred tax assets	597 , 727	391,166	

Deferred tax liabilities - property and equipment, principally due

to differences in depreciation	(16,385)	(13,302)
Deferred tax assets, net	\$581,342	\$377,864

12

NOTE 6 - PROVISION FOR INCOME TAXES (continued)

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods which the deferred tax assets are deductible, management believes it is more likely than not the Company will realize the benefits of these deductible differences. Accordingly, no valuation allowance has been recorded at September 30, 2001 and 2000.

NOTE 7 - RELATED PARTY TRANSACTIONS

Two stockholders who own a combined 50% of the outstanding stock of the Company (including restricted stock) also own 100% of the outstanding stock of ActSys Medical, Inc. The Company has obtained direct financing from this related entity to finance its growth. The Company also sells pharmaceutical products to this entity, purchases pharmaceutical products from this entity and shares certain corporate expenses including wages and insurance.

In November 1999, the Company converted the amount due to this related entity into a term loan agreement that required monthly payments of \$76,701 through November 2001. In August 2000, the term loan was converted into a new loan to expedite the payment terms. This loan required monthly payments of \$119,901 and was paid off during the year ended September 30, 2001.

During the year ended September 30, 2001, the Company also sold pharmaceutical products to another entity related through common ownership and management. The Company also subleases office space to this related entity.

13

NOTE 7 - RELATED PARTY TRANSACTIONS (continued)

The following table summarizes the transactions between the Company and these related entities and the outstanding amounts due to and from these entities at September 2001 and 2000:

	2001	2000
For the years ended September 30:		
Sales	\$6,640,958	\$6,643,586
Rental income	\$ 7 , 164	\$ -0-
Purchases	\$1,152,324	\$1,227,096
Management fees paid, net	\$ 137 , 752	\$ 249,156

Interest expense	\$ 33,289	\$ 133,547
As of September 30:		
Accounts receivable	\$ 204,385	\$ -0-
Due from related party	\$ 39 , 638	\$ -0-
Accounts payable	\$ 45 , 978	\$ -0-
Due to related party	\$ -0-	\$ 32,454
Note pavable - related party	\$ -0-	\$ 925,922

NOTE 8 - EMPLOYEE BENEFIT PLAN

The Company adopted a 401(k) plan on January 1, 2001. All employees of the Company are eligible to participate in a qualified 401(k) Plan. In general, employees may contribute up to 15% of their eligible compensation to the Plan. The Company makes discretionary matching contributions which are determined annually. The Company's contribution to the Plan during the year ended September 30, 2001 was \$55,097.

14

NOTE 9 - COMMITMENTS AND CONTINGENCIES

Lease Commitments

The Company leases office and warehouse facilities under noncancelable operating leases which expire over the next year. These leases generally contain renewal options for periods ranging from one to three years.

The Company subleases a portion of its facilities to an entity related through common ownership and management. This sublease is \$597 per month and is subleased on a month-to-month basis.

Future minimum lease payments are \$92,268 for the year ending September 30, 2002

Rental expense for noncancelable operating leases during the fiscal years ended September 30, 2001 and 2000 was \$104,548 and \$104,330, respectively.

Employment Agreement/Restricted Stock

On August 1, 2000, the Company executed an employment agreement with one of its officers. The agreement calls for a minimum salary of \$100,000 per year through the expiration of the agreement on July 31, 2005. Additionally, on August 1, 2000, the Company issued 20,000 shares of its restricted common stock to the officer as an inducement for the officer to enter into and perform under the terms of the employment agreement.

The value of the 20,000 shares of restricted common stock issued on August 1, 2000 was determined to be \$1,695,549. The value of the stock will be recognized as compensation ratably over the term of the employment agreement. Accordingly, the Company recognized compensation and restricted common stock of \$339,108 and \$56,518 for the years ended September 30, 2001 and 2000, respectively.

Financial Guarantee

The Company has a continuing guarantee of a \$4,000,000 credit facility of a related entity. It is reasonably possible that the Company would be required to make payments under its guarantee. The Company monitors the financial performance of this entity on a monthly basis. No amount has been accrued for the Company's obligations under its guarantee arrangement.

15

NOTE 10 - BUSINESS AND CREDIT CONCENTRATIONS

The Company's operations may be adversely impacted by future federal and state healthcare budget cuts, as a significant portion of the Company's revenue is dependent on certain governmental healthcare programs.

The Company estimates an allowance for doubtful accounts based on the credit worthiness of its customers as well as general economic conditions. Consequently, an adverse change in those factors may affect the Company's estimate of its bad debts.

At September 30, 2001, \$11,365,265 or 90% of the Company's total accounts receivable were due from five customers. Revenues from sales to these customers were approximately 94% of the Company's net sales for the year ended September 30, 2001.

At September 30, 2000, \$5,141,914 or 44% of the Company's total trade accounts receivable were due from one customer. Revenues from sales to this customer were approximately 31% of the Company's net sales for the year ended September 30, 2000.

Two of the Company's suppliers accounted for approximately 68% of total purchases during the year ended September 30, 2001.

Three of the Company's suppliers accounted for approximately 73% of total purchases during the year ended September 30, 2000.

NOTE 11 - DISCLOSURE FOR THE STATEMENT OF CASH FLOWS

Additional Disclosures

Cash paid during the years ended September 30, 2001 and 2000 for:

	2001	2000
Income taxes	\$3,053,672	\$3,396,745
Interest	======= \$ 274,650	\$ 583,346
	=======	

NOTE 11 - DISCLOSURE FOR THE STATEMENT OF CASH FLOWS (continued)

Non Cash Investing and Financing Transactions

During the year ended September 30, 2001, the Company's Board of Directors declared dividends of \$500,000 to be accrued and distributed according to the stockholders' ownership percentages. The accrued dividends increased dividends payable and decreased retained earnings.

During the year ended September 30, 2000, the Company received property and equipment at a net book value of \$26,891 from a related entity and increased the amount due to this entity for the same amount.

During the year ended September 30, 2000, the Company converted \$1,670,525 of the amount due to a related entity to a note payable.

17

APEX THERAPEUTIC CARE, INC. FINANCIAL STATEMENTS AS OF AND FOR THE YEARS ENDED SEPTEMBER 30, 2000 AND 1999

TABLE OF CONTENTS

Independent Auditors' Report

Balance Sheets

Statements of Income and Retained Earnings

Statements of Cash Flows

Notes to Financial Statements

18

INDEPENDENT AUDITORS' REPORT

To the Board of Directors Apex Therapeutic Care, Inc. Westlake Village, California

We have audited the accompanying balance sheets of Apex Therapeutic Care, Inc. as of September 30, 2000 and 1999 and the related statements of income and retained earnings and cash flows for the years then ended. These financial statements are the responsibility of Apex Therapeutic Care, Inc.'s management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Apex Therapeutic Care, Inc. as of September 30, 2000 and 1999 and the results of its operations and its cash flows for the years then ended in conformity with generally accepted accounting principles.

/s/ Martini, Iosue & Akpovi

Encino, California November 2, 2000

19

APEX THERAPEUTIC CARE, INC.
BALANCE SHEETS
SEPTEMBER 30, 2000 AND 1999

ASSETS

	2000	1999
CURRENT ASSETS		
Cash	•	\$ 39,836
Accounts receivable (net of allowance for doubtfu		
accounts of \$543,828 and \$148,828)	11,073,189	12,336,861
Inventory	1,884,478	1,299,756
Other current assets	82,817	21,000
TOTAL CURRENT ASSETS	13,094,564	13,697,453
PROPERTY AND EQUIPMENT, NET	237,716	135,414
OTHER ASSETS		
Deposits	22,267	23,342
Deferred tax assets, net	377,864	56,322
Other assets	77,476	·
TOTAL OTHER ASSETS	477 , 607	195 , 560

TOTAL ASSETS	\$13,809,887 =======	\$14,028,427 =======
LIABILITIES AND STOCKHOLDERS'		
CURRENT LIABILITIES Accounts payable and accrued expenses Income taxes payable Current portion of notes payable Due to affiliate Note payable - affiliate	184,584 14,763	\$ 4,763,862 1,796,791 -0- 1,632,808 -0-
TOTAL CURRENT LIABILITIES	5,700,440	8,193,461
OTHER LIABILITIES Deferred compensation Line of credit Notes payable TOTAL OTHER LIABILITIES TOTAL LIABILITIES	80,937 1,499,456 89,268	1,914,484 -0- 1,914,484 10,107,945
COMMITMENTS AND CONTINGENCIES		
STOCKHOLDERS' EQUITY Common stock, stated value, authorized 1,000,000 issued and outstanding 100,000 shares Common stock - restricted, issued and outstanding 20,000 shares Retained earnings	210,000	-0- 3,910,482
TOTAL STOCKHOLDERS' EQUITY		3,920,482
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$13,809,887	\$14,028,427

The accompanying notes are an integral part of these financial statements

20

APEX THERAPEUTIC CARE, INC. STATEMENTS OF INCOME AND RETAINED EARNINGS FOR THE YEARS ENDED SEPTEMBER 30, 2000 AND 1999

	2000	1999
NET SALES COST OF SALES	\$45,339,312 32,451,828	\$35,218,635 24,072,162
CDOGG DDOGT		
GROSS PROFIT	12,887,484	11,146,473
OPERATING EXPENSES	8,552,586 	5,287,697

INCOME FROM OPERATIONS	4,334,898	5,858,776
OTHER INCOME (EXPENSES)		
Miscellaneous income		20,843
Loss on disposal of assets		-0-
Miscellaneous expense		-0-
Interest expense	(583,346)	(305,838)
NET OTHER EXPENSES	(626 , 596)	(284,995)
INCOME BEFORE PROVISION FOR INCOME TAXES	3,708,302	5,573,781
PROVISION FOR INCOME TAXES	1,445,516	2,171,093
NET INCOME	2,262,786	3,402,688
RETAINED EARNINGS		
Beginning of year	3,910,482	507,794
End of year	\$ 6,173,268	•
	=======	

The accompanying notes are an integral part of these financial statements

21

APEX THERAPEUTIC CARE, INC. STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2000 AND 1999

CASH FLOWS FROM OPERATING ACTIVITIES Net income \$2,262,786 \$ Adjustments to reconcile net income to net cash	3,402,688
provided (used) by operating activities: Provision for bad debts 395,000 Amortization and depreciation 108,160	56,728 15,607
Loss on disposal of assets 19,263 Deferred income tax benefit (321,542)	-0-
Deferred compensation 184,968 Stock-based compensation 56,518	-0- -0-
(Increase) decrease in assets: Accounts receivable 868,672 (1 Inventory (584,722)	
Deposits 1,075 Other assets (62,336)	
Increase (decrease) in liabilities: Accounts payable and accrued expenses (221,145) Income taxes payable (1,612,207)	2,484,667 1,482,864
NET CASH PROVIDED (USED) BY OPERATING ACTIVITIES 1,094,490 (3,990,382)

CASH USED BY INVESTING ACTIVITIES		
Purchase of property and equipment	(163 , 895)	(147,186)
CASH FLOWS FROM FINANCING ACTIVITIES		
Net increase (decrease) in loans from affiliate	(701 , 323)	2,242,272
Net increase (decrease) in line of credit	(415,028)	1,914,484
Proceeds from sale of common stock	200,000	-0-
NET CASH PROVIDED (USED) BY FINANCING		
ACTIVITIES	(916 , 351)	4,156,756
NET INCREASE IN CASH	14,244	19,188
CASH, BEGINNING OF YEAR	39,836	20,648
CACH DND OF VEAD	÷	
CASH, END OF YEAR	\$ 54,080	\$ 39,836
		=

The accompanying notes are an integral part of these financial statements

22

APEX THERAPEUTIC CARE, INC. NOTES TO FINANCIAL STATEMENTS SEPTEMBER 30, 2000 AND 1999

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Apex Therapeutic Care, Inc. (the "Company") is a wholesale distributor of pharmaceutical products consisting primarily of antihemophilic factors and other plasma derived therapeutic agents. The Company's sales are made to pharmacies located in various states throughout the continental United States.

Accounts Receivable

The allowance for doubtful accounts is based on management's evaluation of outstanding accounts receivable at the end of the year given their prior experience with third party insurance company receivables. Bad debt expense for the years ended September 30, 2000 and September 30, 1999 was \$817,564 and \$119,558, respectively.

Inventory

Inventory is stated at the lower of average cost (which approximates first in, first out) or market. Inventory consists of finished goods.

Property and Equipment

Property and equipment are recorded at lower of cost or net realizable value. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from five to seven years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Maintenance and repairs are charged to expense as incurred.

Other Assets

Other assets consist principally of deferred financing fees, organizational costs and security deposits. The deferred financing fees are amortized straight-line over the term of the financing facility. The organizational costs are amortized straight-line over ten years. Accumulated amortization for the deferred financing fees was \$41,730 and \$3,210 and accumulated amortization for organizational costs was \$1,041 and \$625 at September 30, 2000 and September 30, 1999, respectively.

23

APEX THERAPEUTIC CARE, INC. NOTES TO FINANCIAL STATEMENTS SEPTEMBER 30, 2000 AND 1999

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amount of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Use of Estimates

Management of the Company has made a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities to prepare these financial statements in conformity with generally accepted accounting principles. Actual results could differ from those estimates.

NOTE 2 - PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at September 30:

2000 1999

Office furniture and equipment	\$124,484	\$ 52,637
Computer hardware and software	114,539	88,446
Leasehold improvements	52 , 606	-0-
Warehouse equipment	20,479	5 , 076
Convention equipment	1,785	1,027
	313,893	147,186
Less: Accumulated depreciation	(76 , 177)	(11,772)
Property and equipment, net	\$237,716	\$135,414
	======	======

24

APEX THERAPEUTIC CARE, INC. NOTES TO FINANCIAL STATEMENTS SEPTEMBER 30, 2000 AND 1999

NOTE 3 - LINE OF CREDIT

In August 1999, the Company entered into a credit facility with a lender that permits the Company to borrow up to 80% of its eligible receivables. The credit facility has a maximum borrowing limit of \$6,500,000 and expires August 15, 2002. Interest on advances under the terms of this credit facility accrues at a per annum rate of one percent (1%) in excess of the rate of interest announced publicly by Citibank, N.A., from time to time as its "prime rate" (9.50% at September 30, 2000) and is payable monthly. The Company must pay a quarterly fee equal to one-half of one percent (0.5%) on the unused portion of the facility. Amounts owed to the bank under this credit facility are secured by all assets of the Company. The credit facility requires the Company to comply with certain working capital financial covenants. At September 30, 2000, the Company was in compliance with or received waivers for such covenants.

Prior to August 1999, the Company had a credit line agreement with a bank with a maximum borrowing limit of \$1,500,000. Interest on advances under the terms of this line of credit agreement accrued at the bank's prime rate. The balance outstanding was paid off with proceeds from the new credit facility and the agreement was terminated.

NOTE 4 - STOCKHOLDERS' EQUITY

In November 1999, the Company sold 2,000 shares of common stock to an officer of the Company for \$200,000. Subsequently, the Board of Directors amended and restated the Company's articles of incorporation to effect a ten-for-one split of the Company's outstanding common stock. The split of the Company's stock was effected in the form of a stock dividend. Pursuant to the amendment, the Company is authorized to issue 1,000,000 shares of its common stock of which 100,000 shares were issued and outstanding as of September 30, 2000 (also see Note 8).

NOTE 5 - STOCK APPRECIATION RIGHTS

In October 1999, the Company adopted a non-qualified Stock Appreciation Rights

Plan (SAR Plan), whereby selected key employees are granted performance unit rights (SAR Units) which are rights to receive an amount based on the appreciated value of the Company's common stock over an established base price. SAR Units begin vesting on the date of grant and vest at 20% per year for five years. The maximum number of SAR Units that may be granted under the plan is

25

APEX THERAPEUTIC CARE, INC. NOTES TO FINANCIAL STATEMENTS SEPTEMBER 30, 2000 AND 1999

NOTE 5 - STOCK APPRECIATION RIGHTS (continued)

10,000. The maximum term of the plan is ten years. On October 1, 1999, the Company issued 6,750 SAR Units at a weighted average-base price of \$0.125 per unit. The date of grant for these units was deemed by the Company's Board of Directors to be April 1, 1998. During the fiscal year ended September 30, 2000, 2,250 SAR Units were exercised. Upon the exercise of the SAR Units, the appreciated value was determined and the amounts were converted into Notes Payable with a term of 84 months. The notes are subordinate to any amounts due under the Company's Line of Credit and Agreement and bear interest at 9% per annum.

The principal portion of these notes matures as follows during the years ending September 30:

2001	\$ 14,763
2002	12,571
2003	13,750
2004	15,040
2005	16,451
Thereafter	31,456
	\$104,031

In September 2000, an employee forfeited rights to 3,500 SAR Units.

At September 30, 2000, 1,000 SAR Units remain outstanding. As of September 30, 2000, the Company accrued deferred compensation related to these outstanding units of \$80,937.

NOTE 6 - PROVISION FOR INCOME TAXES

The provision (benefit) for income taxes for the years ended September 30, 2000 and 1999 consists of the following:

	2000	1999
Current Deferred	\$1,767,058 (321,542)	\$2,187,134 (16,041)
	\$1,445,516	\$2,171,093

2.6

APEX THERAPEUTIC CARE, INC. NOTES TO FINANCIAL STATEMENTS SEPTEMBER 30, 2000 AND 1999

NOTE 6 - PROVISION FOR INCOME TAXES (continued)

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities at September 30, 2000 and 1999 are presented below:

Deferred tax assets:

	2000	1999
Accounts receivable principally due		
to allowance for doubtful accounts	\$232 , 976	\$ 63,758
Inventory	6 , 075	3 , 759
Accrued stockholder bonus	32,130	-0-
Accrued commissions	31,172	-0-
Accrued vacation	185	-0-
Deferred compensation	64,416	-0-
Stock-based compensation	24,212	-0-
Total deferred tax assets	391,166	67,517
Deferred tax liabilities - property and equipment, principally due to differences		
in depreciation	(13,302)	(11,195)
Deferred tax assets, net	\$377 , 864	\$ 56,322 ======

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods which the deferred tax assets are deductible, management believes it is more likely than not the Company will realize the benefits of these deductible differences. Accordingly, no valuation allowance has been recorded at September 30, 2000 and 1999.

SEPTEMBER 30, 2000 AND 1999

NOTE 7 - RELATED PARTY TRANSACTIONS

Two stockholders who own a combined 50% of the outstanding stock of the Company (including restricted stock) also own 100% of the outstanding stock of ActSys Medical, Inc. (the "affiliate"). The Company has obtained direct financing from the affiliate to finance its growth. The Company also sells pharmaceutical products to the affiliate, purchases pharmaceutical products from the affiliate and shares certain corporate expenses including wages and insurance.

In November 1999, the Company converted the amount due to its affiliate into a term loan agreement that required monthly payments of \$76,701 through November 2001. In August 2000, the term loan was converted into a new loan to expedite the payment terms. The new loan requires monthly payments of \$119,901 through May 2001. The term loan bears interest at a rate of 9.50%.

The following table summarizes the transactions between the Company and its affiliate and the outstanding amounts due to the affiliate at September 2000 and 1999:

	2000	1999
For the years ended September 30:		
Sales	\$6,643,586	\$4,375,037
Purchases	\$1,227,096	\$2,653,116
Management fees paid, net	\$ 249,156	\$ 529 , 836
Interest expense	\$ 133,547	\$ 179 , 139
As of September 30:		
Due to affiliate	\$ 32,454	\$1,632,808
Note payable - affiliate	\$ 925 , 922	\$ -0-

28

APEX THERAPEUTIC CARE, INC. NOTES TO FINANCIAL STATEMENTS SEPTEMBER 30, 2000 AND 1999

NOTE 8 - COMMITMENTS AND CONTINGENCIES

Lease Commitments

The Company leases office and warehouse facilities under noncancelable operating leases which expire over the next two years. These leases generally contain renewal options for periods ranging from one to three years.

Future minimum lease payments are \$111,806 and \$7,200 for the years ended September 30, 2001 and 2002, respectively.

Rental expense for operating leases during the fiscal years ended September 30, 2000 and 1999 was \$104,330 and \$23,178, respectively.

Employment Agreement/Restricted Stock

On August 1, 2000, the Company executed an employment agreement with one of its officers. The agreement calls for a minimum salary of \$100,000 per year through the expiration of the agreement on July 31, 2005. Additionally, on August 1, 2000, the Company issued 20,000 shares of its restricted common stock to the officer as an inducement for the officer to enter into and perform under the terms of the employment agreement.

The value of the 20,000 shares of restricted common stock issued on August 1, 2000 was determined to be \$1,695,549. The value of the stock will be recognized as compensation ratably over the term of the employment agreement. Accordingly, the Company recognized compensation and restricted common stock of \$56,618 for the year ended September 30, 2000.

Legal Proceedings

The Company is a defendant in a lawsuit that alleges the Company obtained customers by using information stolen by a former employee of a competitor. The Company's counsel has indicated that an out of court settlement will most likely be reached and has estimated the settlement to range between \$75,000 and \$150,000. Accordingly, the Company has accrued \$75,000 as of September 30, 2000.

Financial Guarantee

In August 1999, the Company issued a continuing guarantee of a \$3,500,000 credit facility of an affiliated Company. It is reasonably possible that the Company would be required to make payments under its guarantee. The Company monitors the financial performance of the affiliated Company on a monthly basis. No amount has been accrued for the Company's obligations under its guarantee arrangement.

29

APEX THERAPEUTIC CARE, INC. NOTES TO FINANCIAL STATEMENTS SEPTEMBER 30, 2000 AND 1999

NOTE 9 - BUSINESS AND CREDIT CONCENTRATIONS

The Company's operations may be adversely impacted by future federal and state healthcare budget cuts, as a significant portion of the Company's revenue is dependent on certain governmental healthcare programs.

At September 30, 2000, \$5,141,914 or 44% of the Company's total trade accounts receivable were due from one customer. Revenues from sales to this customer were approximately 31% of the Company's net sales for the year ended September 30, 2000.

At September 30, 1999, \$7,051,429 or 54% of the Company's total trade accounts receivable were due from one customer. Revenues from sales to this customer were approximately 51% of the Company's net sales for the year ended September 30, 1999.

The Company estimates an allowance for doubtful accounts based on the credit worthiness of its customers as well as general economic conditions. Consequently, an adverse change in those factors may affect the Company's estimate of its bad debts.

Three of the Company's suppliers accounted for approximately 73% of total purchases during the year ended September 30, 2000.

NOTE 10 - DISCLOSURE FOR THE STATEMENT OF CASH FLOWS

Additional Disclosures

Cash paid during the years ended September 30, 2000 and 1999 for:

	2000	1999
Income taxes	\$3,396,745	\$774 , 237
	=======	
Interest	\$ 583 , 346	\$118 , 560
	========	======

Non Cash Investing and Financing Transactions

During the year ended September 30, 2000, the Company received property and equipment at a net book value of \$26,891 from its affiliate and increased the amount due to its affiliate for the same amount.

During the year ended September 30, 2000, the Company converted \$1,670,525 of the amount due to its affiliate to a note payable.

30

APEX THERAPEUTIC CARE, INC.
UNAUDITED CONDENSED FINANCIAL STATEMENTS
AS OF AND FOR THE QUARTER ENDED
DECEMBER 31, 2001 AND 2000

TABLE OF CONTENTS

Condensed Statements of Operations

Condensed Balance Sheets

Condensed Statements of Cash Flows

Notes to Condensed Financial Statements

31

APEX THERAPEUTIC CARE, INC.
CONDENSED STATEMENTS OF OPERATIONS
(In thousands)
(Unaudited)

	Three Months December 2001	31,
Revenues	\$ 13,262 \$	11,621
Costs and operating expenses:		
Cost of sales and services Selling, general and administrative	9,265 2,576	7,937 1,715
Total costs and operating expenses	11,841	9,652
Income from operations	1,421	1,969
Interest income	3	-
Income before taxes	1,424	1,969
Income taxes	633	890
Net income	\$ 791 \$ =====	1,079 =====

32

APEX THERAPEUTIC CARE, INC. CONDENSED BALANCE SHEETS (In thousands) (Unaudited)

	December 31, 2001	September 30, 2001
ASSETS		
Cash and cash equivalents Accounts receivable, net Inventory Prepaid and other current assets Total current assets	\$ 11 12,157 5,010 75 17,253	11,794
Property and equipment, net Other assets	225 635 	231 682
Total assets	\$18,113 =====	\$17 , 339
LIABILITIES AND STOCKHOLDERS' EQUITY		
Accounts payable and accrued expenses Dividend payable	\$ 6,635 500	\$ 6,240 500
Total current liabilities	7,135	6,740

Long term liability	210	204
Stockholders' equity		
Common stock Retained earnings	690 10 , 078	606 9 , 789
Total stockholders' equity	10,768	10,395
Total liabilities and stockholders' equity	\$18,113 ======	\$17,339 ======

33

APEX THERAPEUTIC CARE, INC. CONDENSED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)

	Three months end	ded December 31, 01 2000		
OPERATING ACTIVITIES				
Net income Adjustments to reconcile net income to net cash (used in) provided by operating activities	·	91 \$ 1,079		
Depreciation and amortization Gain from early extinguishment of deb Changes in operating assets and liabi	t			
NET CASH USED IN PROVIDED BY OPERATING ACTIVITI		5) 662		
INVESTING ACTIVITIES				
Purchase of property and equipment	,	7) (14)		
NET CASH USED IN INVESTING ACTIVITIES		7) (14)		
FINANCING ACTIVITIES				
Borrowing (Repayments) on line of credit and no payable	tes 75	55 (338)		
Loan from affiliate		- (340) 		
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVI		55 (678) 		
DECREASE IN CASH AND CASH EQUIVALENTS		17) (30)		
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIO		57 54		
CASH AND CASH EQUIVALENTS AT END OF PERIOD		\$ 24		

34

NOTES TO CONDENSED FINANCIAL STATEMENTS

Note 1. Basis of Presentation

The condensed financial statements are unaudited and reflect all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. The condensed financial statements should be read in conjunction with the financial statements for the year ended September 30, 2001 and notes thereto. The results of operations for the three months ended December 31, 2001 are not necessarily indicative of the results to be expected for the entire fiscal year ending September 30, 2002.

Note 2. Subsequent events

On February 28, 2002 Apex Therapeutic Care, Inc. was sold to Curative Health Services, Inc. for \$60 million. The sale proceeds consisted of \$19 million in cash, \$5 million in a seller's note and \$36 million (1,806,000 shares) of Curative Health Services, Inc. stock.

35

CURATIVE HEALTH SERVICES, INC. AND SUBSIDIARIES
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF AND FOR THE YEAR ENDED

DECEMBER 31, 2001

TABLE OF CONTENTS

Pro Forma Condensed Consolidated Balance Sheet

Pro Forma Condensed Consolidated Statement of Operations

Notes to Pro Forma Condensed Consolidated Financial Statements

36

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The following unaudited pro forma condensed consolidated financial statements give pro forma effect to the completion of the purchase by Curative Health Services, Inc. of all of the outstanding shares of stock of Apex Therapeutic Care, Inc. for the year ended December 31, 2001. The pro forma financial statements reflect the December 31, 2001 audited balance sheet and statement of

operations of Curative Health Services, Inc. and Subsidiaries and the September 30, 2001 audited balance sheet and statement of income of Apex Therapeutic Care, Inc. The pro forma condensed consolidated financial statements include certain estimates and adjustments, as set forth in the notes to the unaudited condensed consolidated financial statements, and are presented for illustrative purposes only. The pro forma information presented is not necessarily indicative of the results to be expected in the future for Curative Health Services, Inc. and Subsidiaries.

37

CURATIVE HEALTH SERVICES, INC. AND SUBSIDIARIES PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEETS-UNAUDITED AS OF DECEMBER 31, 2001

	Curative Health Services, Inc. and Subsidiaries	Apex Therapeutic Care, Inc.	Consolidating Adjustments
ACCETC			
ASSETS Cash and cash equivalents	\$ 12,264	\$ 757	\$ (4,121)(1),(2
Accounts receivable	13,139	11,794	γ (4,121)(1),(2
Inventory	4,547	3,805	
Deferred tax assets	6 , 265	- -	
Prepaid & other current assets	745	70	_
rrepara a other carrene assects			
Total current assets	36,960	16,426	(4,121)
Property and equipment, net	3 , 795	231	
Goodwill and intangibles, net	34,787	_	49,605(1)
Other assets	1,385	682	2,036(1)
Total assets	\$ 76 , 927	\$ 17 , 339	\$ 47 , 520
	=======	=======	=======
LIABILITIES & STOCKHOLDERS' EQUITY			
Accounts payable	\$ 9,249	\$ 6,123	\$
Accrued expenses and income taxes	25,186	109	
Bank loan	_	8	(8)(1)
Dividends payable	-	500	-
Total current liabilities	34,435	6 , 740	(8)
Long term obligations	6,000	204	5,000 (1)

Commitments and contingencies

Stockholders' equity
Preferred stock, \$.01 par value per
share, 10,000,000 shares
authorized, none issued
Preferred stock, Series A Junior
Participating, par value \$.01 per share,

500,000 shares authorized, none issued

Common stock, \$.01 par value per s	share; 75	606	(577)(1)
Additional paid in capital	34,019		52,894 (1),(2)
Retained earnings	2,398	9,789	(9,789)(1)
Total stockholders' equity	36,492	\$ 10,395	\$ 42 , 528
Total liabilities and	\$ 76 , 927	\$ 17,339	\$ 47 , 520
stockholders' equity	=======	=======	========

38

CURATIVE HEALTH SERVICES, INC. AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENT OF OPERATIONS-UNAUDITED FOR THE YEAR ENDED DECEMBER 31, 2001

Revenues: Services \$ 44,862 \$ - \$ \$ 44,862 Products 36,776 54,536 (6,675)(4) 86,063 Total revenues 81,638 54,536 (6,675)(4) 86,063 Cost of services 25,887 - 25,887 Cost of product sales 29,779 37,821 (6,429)(4) 62,253 Selling, general and 51,466 9,553 - 64,286 administrative Total cost and operating 107,132 47,374 (6,429) (1,426) expense		Services,	_	Consolidating Adjustments	Consolidated pro forma statement of operations
Products 36,776 54,536 (6,675) (4) 86,063 Total revenues 81,638 54,536 (6,675) (4) 86,063 Cost of services 25,887 - 25,887 Cost of product sales 29,779 37,821 (6,429) (4) 62,253 Selling, general and 51,466 9,553 - 64,286 administrative	Revenues:				
Total revenues 81,638 54,536 (6,675) 130,925 Cost of services 25,887 - 25,887 Cost of product sales 29,779 37,821 (6,429)(4) 62,253 Selling, general and 51,466 9,553 - 64,286 administrative	Services				\$ 44,862
Total revenues 81,638 54,536 (6,675) 130,925 Cost of services 25,887 - 25,887 Cost of product sales 29,779 37,821 (6,429)(4) 62,253 Selling, general and 51,466 9,553 - 64,286 administrative	Products		54,536	(6,675)(4)	
Cost of product sales 29,779 37,821 (6,429)(4) 62,253 Selling, general and 51,466 9,553 - 64,286 administrative	Total revenues		54,536	(6,675)	
Cost of product sales 29,779 37,821 (6,429)(4) 62,253 Selling, general and 51,466 9,553 - 64,286 administrative	Cost of services	25.887	_		25.887
administrative Total cost and operating 107,132 47,374 (6,429) 154,426 expense (Loss) income from operations (25,494) 7,162 (246) (18,578) Interest expense - 275 220 (5) 495 Interest income 816 3 90 (5) 909 Net (loss) income before taxes (24,678) 6,890 (376) (18,164) Income tax (benefit) provision (2,473) 2,774 (154) (3) 147 Net (loss) income \$ (22,205) \$ 4,116 \$ (222) \$ (18,311)			37,821	(6,429)(4)	·
Total cost and operating 107,132 47,374 (6,429) 154,426 expense	Selling, general and	51,466	9,553	_	64,286
Closs income from operations (25,494) 7,162 (246) (18,578)					
(Loss) income from operations (25,494) 7,162 (246) (18,578) Interest expense - 275 220 (5) 495 Interest income 816 3 90 (5) 909 Net (loss) income before taxes (24,678) 6,890 (376) (18,164) Income tax (benefit) provision (2,473) 2,774 (154) (3) 147 Net (loss) income \$ (22,205) \$ 4,116 \$ (222) \$ (18,311) Net (loss) income per share, \$ (3.09) \$ \$ (1.82) \$ (1.82) \$ (1.82) \$ (1.82)			•	` '	•
Interest expense	expense				=======
Interest income 816 3 90 (5) 909 Net (loss) income before taxes (24,678) 6,890 (376) (18,164) Income tax (benefit) provision (2,473) 2,774 (154) (3) 147 Net (loss) income \$ (22,205) \$ 4,116 \$ (222) \$ (18,311) Net (loss) income per share, \$ (3.09) \$ (1.82) basic \$ (1.82)	(Loss) income from operations	(25, 494)	7,162	(246)	(18,578)
Interest income 816 3 90 (5) 909 Net (loss) income before taxes (24,678) 6,890 (376) (18,164) Income tax (benefit) provision (2,473) 2,774 (154) (3) 147 Net (loss) income \$ (22,205) \$ 4,116 \$ (222) \$ (18,311) Net (loss) income per share, \$ (3.09) \$ (1.82) basic \$ (1.82)	Interest expense	-	275	220 (5)	495
Income tax (benefit) provision (2,473) 2,774 (154) (3) 147 Net (loss) income \$ (22,205) \$ 4,116 \$ (222) \$ (18,311) Net (loss) income per share, \$ (3.09) \$ (1.82) basic \$ (1.82)	-	816	3		909
Income tax (benefit) provision (2,473) 2,774 (154) (3) 147 Net (loss) income \$ (22,205) \$ 4,116 \$ (222) \$ (18,311) Net (loss) income per share, \$ (3.09) \$ (1.82) basic \$ (1.82)					
Income tax (benefit) provision (2,473) 2,774 (154) (3) 147 Net (loss) income \$ (22,205) \$ 4,116 \$ (222) \$ (18,311) Net (loss) income per share, \$ (3.09) \$ (1.82) basic \$ (1.82)	Net (loss) income before taxes	(24,678)	6,890	(376)	(18,164)
Net (loss) income \$ (22,205) \$ 4,116 \$ (222) \$ (18,311) ===================================					
Net (loss) income \$ (22,205) \$ 4,116 \$ (222) \$ (18,311) Net (loss) income per share, basic \$ (3.09) \$ (1.82)	Income tax (benefit) provision				
Net (loss) income per share, \$ (3.09) \$ (1.82) basic ========	Net (loss) income				
basic ====================================		=======	=======	=======	=======
basic ====================================	Net (loss) income per share	\$ (3.09)			\$ (1.82)
					, , , , ,
Net (loss) income per share, \$ (3.09) \$ (1.82)	20010				
	Net (loss) income per share,	\$ (3.09)			\$ (1.82)

diluted	====	=====		=======
Weighted average	shares, basic	7,193	120	10,058 (6)
		=====	===	=====
Weighted average	shares,	7,193	120	10,058 (6)
diluted		=====	===	=====

39

On February 28, 2002 Apex Therapeutic Care, Inc. was sold to Curative Health Services, Inc. for \$60 million. The sale proceeds consisted of \$19 million in cash, \$5 million in a seller's note and \$36 million (1,806,000 shares) of Curative Health Services, Inc. stock.

NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Details of the pro forma adjustments relating to the acquisition of Apex Therapeutic Care, Inc. follow.

- 1) To record the effect of the stock purchase of Apex Therapeutic Care, Inc. on cash balances, equity accounts, long term debt and the repayment of the outstanding debt of Apex Therapeutic Care, Inc. Also reflects a loan of \$2.036 million made to a former shareholder at closing. The purchase price allocation and amounts allocated to goodwill and other intangibles are preliminary and are subject to finalization of valuation.
- 2) To record the effect of the \$16.9 million private placement stock offering on cash and equity accounts. The proceeds from the private placement were utilized for the purchase of Apex Therapeutic Care, Inc. and working capital needs.
- 3) To record additional tax benefit.
- 4) To eliminate affiliate sales, cost of sales and profit not anticipated to occur post acquisition.
- 5) Record interest expense on \$5.0 million sellers' note recorded as part of Apex Therapeutic Care, Inc. purchase and interest income on \$2.036 million loan given to former shareholder.
- 6) Total of 2.865 million shares added to reflect shares used for purchase of Apex Therapeutic Care, Inc. stock (1.806 million) and the issuance of the private placement shares (1.059 million).

40

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934,

the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

CURATIVE HEALTH SERVICES, INC.

Date: May 3, 2002 By /s/ Thomas Axmacher

Thomas Axmacher Chief Financial Officer

Exhibit 23-1

CONSENT OF INDEPENDENT AUDITORS

We consent to the incorporation by reference in the Registration Statement (Form S-3 No. 333-83342) and related Prospectus of Curative Health Services, Inc. pertaining to the registration of 1,059,000 shares of its common stock, in the Registration Statement (Form S-8 No. 333-73376) pertaining to Curative Health Services, Inc. 2001 Broad-Based Stock Incentive Plan and Non-Qualified Stock Option Agreements for David Lawson, Steven Michurski, and Beth Oliver, in the Registration Statement (Form S-8 No. 333-60854) pertaining to Curative Health Services, Non-Employee Director Stock Option Plan, as amended, in the Registration Statement (Form S-8 No. 333-60852) pertaining to Curative Health Services, Inc. 2000 Stock Incentive Plan in the Registration Statement (Form S-8 No. 333-65751) pertaining to the Curative Health Services, Inc. and subsidiaries 1991 Stock Option Plan, as amended, in the Registration Statement (Form S-8 No. 333-65753) pertaining to Curative Health Services, Inc. Non-Employee Director Stock Option Plan, amended, in the Registration Statement (Form S-8 No. 33-19370) pertaining to the Curative Health Services, Inc. and subsidiaries Director Share Purchase Program and in the Registration Statement (Form S-8 No. 33-85188) pertaining to the Curative Health Services, Inc. and subsidiaries Employee 401(k) Savings Plan of our report dated November 2, 2000 with respect to the consolidated financial statements of Apex Therapeutic Care, Inc. as of and for the years ended September 30, 2000 and 1999, and of our report dated November 30, 2001 with respect to the consolidated financial statements of Apex Therapeutic Care, Inc. as of and for the years ended September 30, 2001 and 2000 included in Amendment No. 1to the Current Report (Form 8-K) of Curative Health Services, Inc. originally filed on March 11, 2002.

/s/ Martini, Iosue & Akpovi

Encino, California May 3 , 2002